(NYSE: TEVA) Teva Pharmaceutical Industries's forecast annual revenue growth rate of 1.31% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 4.14%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.68%.
Teva Pharmaceutical Industries's revenue in 2025 is $16,616,000,000.On average, 6 Wall Street analysts forecast TEVA's revenue for 2025 to be $19,468,938,158,314, with the lowest TEVA revenue forecast at $19,293,011,720,955, and the highest TEVA revenue forecast at $19,674,146,480,772. On average, 6 Wall Street analysts forecast TEVA's revenue for 2026 to be $19,445,971,434,178, with the lowest TEVA revenue forecast at $19,310,560,206,737, and the highest TEVA revenue forecast at $19,633,268,831,539.
In 2027, TEVA is forecast to generate $19,910,154,116,215 in revenue, with the lowest revenue forecast at $19,483,292,360,900 and the highest revenue forecast at $20,303,598,049,196.